Medherant has been selected for its versatile, easy to use and solvent-free transdermal drug delivery platform: the TEPI Patch.
The TEPI Patch is based upon a novel poly(ether-urethane)/silicone pressure sensitive adhesive that allows a wider range of drugs to be delivered across the skin.
The Company has also created a novel high-throughput analytical system to facilitate the rapid development of its own and third party TEPI Patches.
Nigel Davis, CEO of Medherant, said: “We are delighted to have been shortlisted for this prestigious competition. Recognition of our technology from the RSC is further evidence of the innovative nature of our TEPI Patch technology and the progress we have made towards developing a product that will be easier for patients to use.”
Shortlisted entrants will pitch their ideas to a panel of experts in front of a live audience at the RSC’s annual flagship event for industry, Chemistry Means Business. This event will be held in Manchester, UK on the 13-14 June 2017, where a winner will be selected.
Dr Gabit Nurumbetov, a senior scientist at Medherant, will also be presenting the TEPI Patch technology at this event.
Nicola Broughton, Head of Universities at Mercia Technologies, said: “It is fantastic to see Medherant’s innovative TEPI Patch technology recognised in the RSC competition. It offers huge potential benefits for patients in need of an alternative way of receiving their medication. Mercia is pleased to support the Medherant team as it continues to grow and scale its business.”
